Q3 2026
Released Nov 4, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001653477-26-000064
What the release said
Ingevity reports third quarter 2026 financial results Third Quarter 2026 Results and Recent Highlights:
Adjusted EBITDA from continuing operations was $108.0 million, and Ingevity narrowed its full-year 2026 adjusted EBITDA outlook to $385 million to $395 million, maintaining the midpoint of the prior range.¶2¶3
Third quarter free cash flow was $85.5 million, and share repurchases totaled approximately $39 million at a weighted average price of $71.45 per share.¶4¶5
The company continues to advance the sale of Advanced Polymer Technologies, and the timing of an announced agreement may extend into early 2027.¶6
- Net sales
- $305.1 million¶7
- Net income from continuing operations
- $51.1 million¶8
- Diluted EPS from continuing operations
- $1.46 per diluted share¶8
- Adjusted diluted EPS from continuing operations
- $1.63¶9
- Adjusted EBITDA from continuing operations
- $108.0 million¶2
- Full year 2026 adjusted EBITDA outlook
- $385 million to $395 million Narrowed range for full year 2026, midpoint of prior range maintained¶3
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $305.10M | $333.10M | $333.80M | $446.00M |
| Net Income | $49.30M | $43.50M | -$107.20M | $25.20M |
| EPS Diluted | $1.41 | $1.18 | -$2.94 | $0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ingevity Corp · CIK 1653477 · Engraved from SEC EDGAR